Clearside Biomedical Announces Presentations at the American Academy of Ophthalmology 2023 Annual Meeting
November 02, 2023 07:05 ET
|
Clearside Biomedical, Inc.
Clearside Biomedical announced that multiple oral & poster presentations will be delivered at the American Academy of Ophthalmology (AAO) 2023 Annual Mtg.
Amydis Launches Phase 2 Glaucoma Clinical Program Using Novel Retinal Tracer to Detect Amyloid Beta
November 02, 2023 07:00 ET
|
Amydis, Inc.
Amydis announces Phase 2 clinical program for its novel retinal tracer, AMDX-2011P, to detect amyloid-beta in glaucoma patients.
Rate of Switching from Regeneron’s Eylea to Genentech’s Vabysmo Doubled Over Past Year for Diabetic Macular Edema
November 01, 2023 14:55 ET
|
Spherix Global Insights
Exton, Pennsylvania, Nov. 01, 2023 (GLOBE NEWSWIRE) -- As U.S. ophthalmologists increasingly embrace a wider array of treatment options, the landscape of the diabetic macular edema (DME) market has...
Ashvattha Therapeutics Announces First Patient Dosed via Subcutaneous Administration of Anti-Angiogenic Therapeutic D-4517.2 for Wet AMD and DME in Phase 2 Chronic Dosing Study
November 01, 2023 08:30 ET
|
Ashvattha Therapeutics
Open-label study will evaluate the safety and efficacy of chronic D-4517.2 dosing in patients with wet age-related macular degeneration (wet AMD) or diabetic macular edema (DME)Favorable safety and...
Oculis to Present a Late-Breaking Abstract at the American Academy of Ophthalmology 2023 Annual Meeting on the Positive Stage 1 Results from Phase 3 DIAMOND Trial for Diabetic Macular Edema
November 01, 2023 06:30 ET
|
Oculis Holding AG
ZUG, Switzerland and BOSTON, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company purposefully driven to save sight and...
TearSolutions, Inc. Appoints Robert Dempsey to its Board of Directors
November 01, 2023 06:00 ET
|
TearSolutions, Inc.
CHARLOTTESVILLE, Va., Nov. 01, 2023 (GLOBE NEWSWIRE) -- TearSolutions, Inc., a privately held biotech company developing potentially disruptive therapies for the treatment of Dry Eye Disease (DED)...
Curative Biotechnology, Inc. Announces Nomination of Dr. Jeffrey Liebmann to Board of Directors
October 31, 2023 09:45 ET
|
Curative Biotechnology, Inc.
Appointment of Independent Director to become effective upon approval by and listing of common stock on a National Exchange Boca Raton, FL, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Curative Biotechnology...
Alimera Announces Scientific Data Highlighting ILUVIEN® To Be Presented at the American Academy of Ophthalmology
October 31, 2023 08:00 ET
|
Alimera Sciences, Inc.
ATLANTA, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners...
RetinalGeniX IRB Approved to Conduct Study to Personalize Medical Evaluations for Patients Receiving Treatment for Wet Macular Degeneration
October 30, 2023 14:51 ET
|
RetinalGeniX Technologies, Inc.
Proposed patient selection process is intended to reduce the cost and improve the safety and efficacy of patient candidate selection for ocular injections
Nextech to Highlight Ophthalmology Solution Innovations at AAO Conference
October 30, 2023 10:42 ET
|
Nextech Systems, Inc.
Nextech will showcase transformative innovations to its ophthalmology industry-leading software at the AAO 2023 conference from Nov. 3-6.